Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1)
Authors: Kurzrock, R. et al.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Volume: 28
Pages: iii98-iii99
eISSN: 1569-8041
DOI: 10.1093/annonc/mdx261.280
Source: Scopus
Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1).
Authors: Kurzrock, R. et al.
Journal: Ann Oncol
Volume: 28 Suppl 3
Pages: iii98-iii99
eISSN: 1569-8041
DOI: 10.1093/annonc/mdx261.280
Source: PubMed